Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mark Rosin, University of Saskatchewan
ClinicalTrials.gov Identifier:
NCT01574105
First received: March 6, 2012
Last updated: July 3, 2014
Last verified: July 2014
Results First Received: June 18, 2013  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Condition: Coronary Artery Disease

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Began May 1, 2012 Completed January 15, 2013 Patients identified in preadmission clinic or ward.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Exclusion criteria included: renal failure, liver dysfunction, baseline INR >1.5, clotting factor deficiencies, intra-aortic balloon pump therapy, emergency surgery, pregnancy, ejection fraction less than 50%, age less than 18 years, pulmonary hypertension infectious endocarditis, and history of heparin induced thrombocytopenia.

Reporting Groups
  Description
Heparin Resistant Patients whose heparin dose response slope was 89 sec/iu/ml or lower prior to surgery.
Heparin Sensitive Patients whose heparin dose response slope was 90 sec/iu/ml or higher prior to surgery.

Participant Flow:   Overall Study
    Heparin Resistant     Heparin Sensitive  
STARTED     29     37  
COMPLETED     29     37  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Heparin Resistant Patients whose heparin dose response slope was 89 sec/iu/ml or lower prior to surgery.
Heparin Sensitive Patients whose heparin dose response slope was 90 sec/iu/ml or higher prior to surgery.
Total Total of all reporting groups

Baseline Measures
    Heparin Resistant     Heparin Sensitive     Total  
Number of Participants  
[units: participants]
  29     37     66  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     11     16     27  
>=65 years     18     21     39  
Age  
[units: years]
Mean ± Standard Deviation
  67.4  ± 9.8     67.8  ± 9.4     67.6  ± 9.5  
Gender  
[units: participants]
     
Female     3     5     8  
Male     26     32     58  
Region of Enrollment  
[units: participants]
     
Canada     29     37     66  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Chest Tube Losses   [ Time Frame: Chest tube losses are recorded from departure from operating room to chest tube removal in the ICU (normally less than 24 hrs) ]

2.  Secondary:   Transfusion Events   [ Time Frame: Data collection begins with patient arrival in the operating room and ends with discharge from the ICU (normally less than 24hrs) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Mark Rosin
Organization: Saskatoon Health Region
phone: 306-655-2128
e-mail: mark.rosin@sasktoonhealthregion.ca


No publications provided


Responsible Party: Mark Rosin, University of Saskatchewan
ClinicalTrials.gov Identifier: NCT01574105     History of Changes
Other Study ID Numbers: 12-37
Study First Received: March 6, 2012
Results First Received: June 18, 2013
Last Updated: July 3, 2014
Health Authority: Canada: Ethics Review Committee